Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and anlotinib in second-line pancreatic cancer
NCT05681390Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and anlotinib in pancreatic cancer (PC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Median Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
tislelizumabanlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05681390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681390.